BAIT
DOT1L
DOT1, KMT4
DOT1-like histone H3K79 methyltransferase
GO Process (3)
GO Function (3)
GO Component (0)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Homo sapiens
PREY
YWHAB
GW128, HEL-S-1, HS1, KCIP-1, YWHAA, RP1-148E22.1
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta
GO Process (22)
GO Function (6)
GO Component (7)
Gene Ontology Biological Process
- Fc-epsilon receptor signaling pathway [TAS]
- MAPK cascade [TAS]
- RNA metabolic process [TAS]
- Ras protein signal transduction [TAS]
- activation of MAPKK activity [TAS]
- apoptotic process [TAS]
- axon guidance [TAS]
- cytoplasmic sequestering of protein [IDA]
- epidermal growth factor receptor signaling pathway [TAS]
- fibroblast growth factor receptor signaling pathway [TAS]
- gene expression [TAS]
- hippo signaling [TAS]
- innate immune response [TAS]
- insulin receptor signaling pathway [TAS]
- intrinsic apoptotic signaling pathway [TAS]
- mRNA metabolic process [TAS]
- membrane organization [TAS]
- negative regulation of protein dephosphorylation [IDA]
- neurotrophin TRK receptor signaling pathway [TAS]
- positive regulation of catalytic activity [IDA]
- positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [TAS]
- small GTPase mediated signal transduction [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Affinity Capture-MS
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.
Publication
Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor alpha (ER?) signaling to the genome. Targeting components of the ER? pathway in these tumors represents, therefore, a rational way ... [more]
Breast Cancer Res Dec. 18, 2021; 24(1);52 [Pubmed: 35850772]
Throughput
- Low Throughput
Curated By
- BioGRID